Evidence map›Paper›PMID 34749739›Full record

ArticleJournal of translational medicine2021

Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART).

Jordana Kron, Thomas Crawford, Virginia Mihalick, Frank Bogun, Jennifer H Jordan, Todd Koelling, Huzaefah Syed, Aamer Syed, Thomas Iden, Kelly Polly and 14 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04017936 (Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04017936 phase2completednot on this map

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2020 to 2024Enrolled17ConditionsCardiac SarcoidosisArmsAnakinra
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Americas Association of Sarcoidosis and other granulomatous disorders 2024 conference highlights.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Interleukin-1 Blockade in Cardiac Sarcoidosis: A Pilot Study.Circulation. Arrhythmia and electrophysiology · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 2 countries.

Jordana KronVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA. jordana.kron@vcuhealth.org.ORCID 0000-0002-3397-0535
Thomas CrawfordCardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
Virginia MihalickVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Frank BogunCardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
Jennifer H JordanVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Todd KoellingCardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
Huzaefah SyedDivision of Rheumatology, Virginia Commonwealth University, Allergy, and Immunology, Richmond, VA, USA.
Aamer SyedDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Thomas IdenDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Kelly PollyDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Emily FedermannVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Kirsta BrayCardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
Sangeeta Lathkar-PradhanCardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
Shilpa JastiVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Lynda RosenfeldSection of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
David BirnieUniversity of Ottawa Heart Institute, Ottawa, ON, Canada.
Melissa SmallfieldVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Le KangDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
Alpha Berry FowlerDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Amy LaddVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Kenneth EllenbogenVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Benjamin Van TassellVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
W Gregory HundleyVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Antonio AbbateVCU Pauley Heart Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, P.O. Box 980053, Richmond, VA, 23298-0053, USA.
Virginia Commonwealth University · USUniversity of Michigan · USUniversity of Ottawa · CAYale University · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Feasibility and Safety of Interleukin-1 Blockade to Treat Cardiac SarcoidosisR21TR003103 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABBATE, ANTONIO, KRON, JORDANA · 2020 to 2021
$491k
American Heart Association 19CSL0134580004NCATS NIH HHS R21 TR003103NCATS NIH HHS TR003103-01NCATS NIH HHS UL1 TR002649Pauley Heart Center Pilot Grant
6 · The paper itself

Abstract

backgroundSarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50 years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-kB, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis.

methodsBuilding on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100 mg daily on top of standard of care versus standard of care only for 28 days and followed for 180 days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis. DISCUSSION: The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities. Trial Registration The trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.

Indexed as

MyocarditisSarcoidosisFemaleGranulomaHumansInterleukin-1Interleukin 1 Receptor Antagonist ProteinPilot ProjectsRandomized Controlled Trials as TopicTranslational Science, BiomedicalTreatment OutcomeInterleukin-1Interleukin 1 Receptor Antagonist ProteinCardiac sarcoidosisHeart failureInflammationInterleukin-1

Identifiers

PMID34749739
PMCPMC8575149
OpenAlexW3214404592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.